Abstract：：Objective To investigate the relation between Homocysteineon and coronary disease on Hypertensive Patients. Methods A number of 5935hypertensive patients who are over 20 years old and lived over 6 months from 60 communities in Shenzhen Nanshan district were assured by sampling method, and they were conducted a questionnaire survey, physical measurements and laboratory testing. We used Chi-square Test, structure Logistic regression model and analysis the interaction between traditional risk factors and Hcy, and used Classification analysis to evaluate the validity of the Logistic regression model. Results (1) The mean of Hcy in Patients with hypertension and stroke was 14.5μmol/L, and it was 12.7μmol/L in control group, there was statistically significant difference between two groups( P<0.001). The prevalence of hyperhomocysteinemia was 46.0% in patients with hypertension and stroke, 30.9% in control group, there was also statistically significant difference between two groups（P<0.001）.(2) After adjusted the related factors of M2, for every 5μmol/L increase in Hcy the OR for stroke was 1.10(1.05-1.15) in total, 1.10(1.05-1.16) in male and 1.12(1.02-1.24) in female;(3)The highest quartile of Hcy（Q4）compared to the lowest quartile of Hcy (Q1) was 1.91(1.21-3.02)in total, 1.45(0.82-2.55) in men and 3.57(1.53-8.35) in women, it is stronger effect in female; P-trend was 0.0021 showed that was statistically significant between different quantile of Hcy in female. No significant interactions between homocysteine and the above stratified factors on the presence of stroke was found. Conclusion An elevated Hcy would increase the risk of the prevalence of stroke in hypertensive patients.
黄少芬, 肖军, 胡峥, 陈忠伟, 陈思韩, 王长义. 高血压患者同型半胱氨酸与脑卒中的关系分析[J]. 实用预防医学, 2015, 22(10): 1184-1188.
Huang Shaofen, Xiao Jun, Hu Zheng, Chen Zhongwei, Chen Sihan, Wang Changyi. The analysis of the relation between Homocysteineon and Stroke on Hypertensive Patients. , 2015, 22(10): 1184-1188.
[1] Bank TW: Toward a Healthy and Harmonious Life in China: Stemming the Rising Tide of Non-Communicable Diseases. In. [2] Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R et al: Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 2006, 113(10):e409-449. [3] Nygard O, Refsum H, Ueland PM, Vollset SE: Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study. Am J Clin Nutr 1998, 67(2):263-270. [4] Lu H, Lu ZH, Li PG, Wang YY, Yan ZY: Elevated homocysteine and hypertension in Xinjiang Province, China. Ethn Dis 2010, 20(1):7-10. [5] 吕纯芳,张涛,李丽玲等. MTHFR基因多态性对药物联合干预H型高血压血浆Hcy 动态监测的影响. 实用预防医学, 2013, 20(12):1509-1511. [6] 张涛,吕纯芳,刘琨等. 高血压患者血浆同型半胱氨酸与年龄、性别、尿酸及血脂的相关性分析. 实用预防医学, 2013, 20(7):786-788. [7] Pencina MJ, D'Agostino RB, Sr., D'Agostino RB, Jr., Vasan RS: Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27(2):157-172; discussion 207-112. [8] Veeranna V, Zalawadiya SK, Niraj A, Pradhan J, Ference B, Burack RC, Jacob S, Afonso L: Homocysteine and reclassification of cardiovascular disease risk. J Am Coll Cardiol 2011, 58(10):1025-1033. [9] O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, Islam S, Pais P, McQueen MJ et al: Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010, 376(9735):112-123. [10] Tanne D, Haim M, Goldbourt U, Boyko V, Doolman R, Adler Y, Brunner D, Behar S, Sela BA: Prospective study of serum homocysteine and risk of ischemic stroke among patients with preexisting coronary heart disease. Stroke 2003, 34(3):632-636. [11] Cui R, Moriyama Y, Koike KA, Date C, Kikuchi S, Tamakoshi A, Iso H: Serum total homocysteine concentrations and risk of mortality from stroke and coronary heart disease in Japanese: The JACC study. Atherosclerosis 2008, 198(2):412-418. [12] Rueda-Clausen CF, Cordoba-Porras A, Bedoya G, Silva FA, Zarruk JG, Lopez-Jaramillo P, Villa LA: Increased plasma levels of total homocysteine but not asymmetric dimethylarginine in Hispanic subjects with ischemic stroke FREC-VI sub-study. Eur J Neurol 2012, 19(3):417-425. [13] Iso H, Moriyama Y, Sato S, Kitamura A, Tanigawa T, Yamagishi K, Imano H, Ohira T, Okamura T, Naito Y et al: Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese. Circulation 2004, 109(22):2766-2772. [14] Ashjazadeh N, Fathi M, Shariat A: Evaluation of Homocysteine Level as a Risk Factor among Patients with Ischemic Stroke and Its Subtypes. Iran J Med Sci 2013, 38(3):233-239. [15] Hao L, Ma J, Zhu J, Stampfer MJ, Tian Y, Willett WC, Li Z: High prevalence of hyperhomocysteinemia in Chinese adults is associated with low folate, vitamin B-12, and vitamin B-6 status. J Nutr 2007, 137(2):407-413. [16] Fan FF, Huo Y, Wang X, Xu X, Wang BY, Xu XP, Li JP: Effect of enalapril on plasma homocysteine levels in patients with essential hypertension. J Zhejiang Univ Sci B 2010, 11(8):583-591. [17] Hu DY, Xu XP: [Prevention of stroke relies on valid control "H" type hypertension]. Zhonghua Nei Ke Za Zhi 2008, 47(12):976-977. [18] Quinlivan EP, Gregory JF, 3rd: Effect of food fortification on folic acid intake in the United States. Am J Clin Nutr 2003, 77(1):221-225. [19] Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH, Sheahan RG, Israelsson B et al: Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA : the journal of the American Medical Association 1997, 277(22):1775-1781. [20] Zhang H, Tao X, Wu J: Association of homocysteine, vitamin B12, and folate with bone mineral density in postmenopausal women: a meta-analysis. Arch Gynecol Obstet 2013. [21] Bonassi Machado R, Chada Baracat E, Eduardo Fernandes C, Marcelo Lakryc E, Rodrigues De Lima G: Effects of estrogen and estrogen-progestogen therapy on homocysteine levels and their correlation with carotid vascular resistance. Gynecol Endocrinol 2007, 23(11):619-624. [22] Gaikwad NW: Mass spectrometry evidence for formation of estrogen-homocysteine conjugates: Estrogens can regulate homocysteine levels. Free Radic Biol Med 2013.
2015, Vol. 22 
